{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:36:33Z","timestamp":1792532193638,"version":"4.5.0"},"reference-count":128,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T00:00:00Z","timestamp":1613779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Varicella-zoster virus (VZV), a common and ubiquitous human-restricted pathogen, causes a primary infection (varicella or chickenpox) followed by establishment of latency in sensory ganglia. The virus can reactivate, causing herpes zoster (HZ, shingles) and leading to significant morbidity but rarely mortality, although in immunocompromised hosts, VZV can cause severe disseminated and occasionally fatal disease. We discuss VZV diseases and the decrease in their incidence due to the introduction of live-attenuated vaccines to prevent varicella or HZ. We also focus on acyclovir, valacyclovir, and famciclovir (FDA approved drugs to treat VZV infections), brivudine (used in some European countries) and amenamevir (a helicase-primase inhibitor, approved in Japan) that augur the beginning of a new era of anti-VZV therapy. Valnivudine hydrochloride (FV-100) and valomaciclovir stearate (in advanced stage of development) and several new molecules potentially good as anti-VZV candidates described during the last year are examined. We reflect on the role of antiviral agents in the treatment of VZV-associated diseases, as a large percentage of the at-risk population is not immunized, and on the limitations of currently FDA-approved anti-VZV drugs. Their low efficacy in controlling HZ pain and post-herpetic neuralgia development, and the need of multiple dosing regimens requiring daily dose adaptation for patients with renal failure urges the development of novel anti-VZV drugs.<\/jats:p>","DOI":"10.3390\/molecules26041132","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T22:04:15Z","timestamp":1613945055000},"page":"1132","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Advances and Perspectives in the Management of Varicella-Zoster Virus Infections"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-4896","authenticated-orcid":false,"given":"Graciela","family":"Andrei","sequence":"first","affiliation":[{"name":"Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snoeck","sequence":"additional","affiliation":[{"name":"Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,20]]},"reference":[{"key":"ref_1","first-page":"25","article-title":"Varicella zoster virus: Natural history and current therapies of varicella and herpes zoster","volume":"14","author":"Breuer","year":"2007","journal-title":"Herpes"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","article-title":"Advances in the understanding of the pathogenesis and epidemiology of herpes zoster","volume":"48","author":"Gershon","year":"2010","journal-title":"J. Clin. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/jmv.21447","article-title":"Disseminated varicella with multiorgan failure in an immunocompetent adult","volume":"81","author":"Defaux","year":"2009","journal-title":"J. Med. Virol."},{"key":"ref_4","first-page":"402","article-title":"Disseminated Varicella-Zoster Virus After Vaccination in an Immunocompetent Patient","volume":"116","author":"Scotch","year":"2016","journal-title":"J. Am. Osteopath. Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Petrun, B., Williams, V., and Brice, S. (2015). Disseminated varicella-zoster virus in an immunocompetent adult. Dermatol. Online J., 21.","DOI":"10.5070\/D3213022343"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1111\/tid.13062","article-title":"Fatal disseminated visceral varicella zoster virus infection in a renal transplant recipient","volume":"21","author":"Loftus","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref_7","first-page":"321","article-title":"Atypical disseminated herpes zoster: Management guidelines in immunocompromised patients","volume":"100","author":"Lewis","year":"2017","journal-title":"Cutis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1742-1241.2009.02089.x","article-title":"Postherpetic neuralgia in the elderly","volume":"63","author":"Johnson","year":"2009","journal-title":"Int. J. Clin. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S1386-6532(10)70003-2","article-title":"The impact of varicella zoster virus: Chronic pain","volume":"48","author":"Opstelten","year":"2010","journal-title":"J. Clin. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/erv.10.31","article-title":"Herpes zoster: A common disease that can have a devastating impact on patients\u2019 quality of life","volume":"9","author":"McElhaney","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/ICL.0000000000000591","article-title":"Herpes Zoster Ophthalmicus Review and Prevention","volume":"45","author":"Davis","year":"2019","journal-title":"Eye Contact Lens."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/WNO.0000000000000721","article-title":"Neurological and Ophthalmological Manifestations of Varicella Zoster Virus","volume":"39","author":"Kedar","year":"2019","journal-title":"J. Neuroophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/infdis\/jiy358","article-title":"High Viral Diversity and Mixed Infections in Cerebral Spinal Fluid from Cases of Varicella Zoster Virus Encephalitis","volume":"218","author":"Depledge","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.jaad.2010.07.011","article-title":"Chronic mucocutaneous herpes simplex virus and varicella zoster virus infections","volume":"66","author":"Wauters","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/2051013615599151","article-title":"Herpes zoster epidemiology, management, and disease and economic burden in Europe: A multidisciplinary perspective","volume":"3","author":"Johnson","year":"2015","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ncl.2008.03.011","article-title":"Varicella zoster virus infection: Clinical features, molecular pathogenesis of disease, and latency","volume":"26","author":"Mueller","year":"2008","journal-title":"Neurol. Clin."},{"key":"ref_17","unstructured":"Bergstrom, R., and Tripathy, K. (2019). Acute Retinal Necrosis, StatPearls."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/eye.1995.53","article-title":"Progressive outer retinal necrosis (PORN) in AIDS patients: A different appearance of varicella-zoster retinitis","volume":"9","author":"Pavesio","year":"1995","journal-title":"Eye"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jcv.2006.12.012","article-title":"Progressive outer retinal necrosis in the era of highly active antiretroviral therapy: Successful management with intravitreal injections and monitoring with quantitative PCR","volume":"38","author":"Yin","year":"2007","journal-title":"J. Clin. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0953-4431(00)00052-7","article-title":"Progressive outer retinal necrosis syndrome: A comprehensive review of its clinical presentation, relationship to immune system status, and management","volume":"12","author":"Austin","year":"2000","journal-title":"Clin. Eye Vis. Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1155\/2019\/4213162","article-title":"Varicella Zoster Meningitis, Optic Neuritis Preceding the Development of Posterior Outer Retinal Necrosis, and Central Retinal Artery Occlusion in a HIV Patient","volume":"2019","author":"Gunturu","year":"2019","journal-title":"Case Rep. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e1389","DOI":"10.1542\/peds.2012-3303","article-title":"Long-term effectiveness of varicella vaccine: A 14-Year, prospective cohort study","volume":"131","author":"Baxter","year":"2013","journal-title":"Pediatrics"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Marin, M., Leung, J., and Gershon, A.A. (2019). Transmission of Vaccine-Strain Varicella-Zoster Virus: A Systematic Review. Pediatrics, 144.","DOI":"10.1542\/peds.2019-1305"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1128\/JVI.00437-15","article-title":"Recombination of Globally Circulating Varicella-Zoster Virus","volume":"89","author":"Norberg","year":"2015","journal-title":"J. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jama.2019.9053","article-title":"Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial","volume":"322","author":"Bastidas","year":"2019","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2165\/00003495-199652050-00009","article-title":"Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections","volume":"52","author":"Perry","year":"1996","journal-title":"Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2165\/00003495-199550020-00011","article-title":"Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections","volume":"50","author":"Perry","year":"1995","journal-title":"Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1128\/AAC.33.10.1765","article-title":"Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 (9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir)","volume":"33","author":"Hodge","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","article-title":"Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster","volume":"68","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000150567","article-title":"Antiviral therapy of herpes simplex and varicella-zoster virus infections","volume":"40","author":"Wutzler","year":"1997","journal-title":"Intervirology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e626","DOI":"10.1097\/MJT.0000000000000436","article-title":"Comparison of Famciclovir, Valaciclovir, and Brivudine Treatments in Adult Immunocompetent Patients with Herpes Zoster","volume":"25","author":"Yaldiz","year":"2018","journal-title":"Am. J. Ther."},{"key":"ref_32","first-page":"1094","article-title":"Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice","volume":"46","author":"Desgranges","year":"1986","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/1120009X.2019.1665875","article-title":"A life-threatening drug-drug interaction between capecitabine and brivudine in a patient with metastatic breast cancer","volume":"31","author":"Tsifi","year":"2019","journal-title":"J. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrclinonc.2009.185","article-title":"Interaction between capecitabine and brivudin in a patient with breast cancer","volume":"7","author":"Canada","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/02841860802660502","article-title":"Fatal drug-drug interaction of brivudine and capecitabine","volume":"48","author":"Bravo","year":"2009","journal-title":"Acta Oncol."},{"key":"ref_36","first-page":"791","article-title":"A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs","volume":"287","author":"Okuda","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_37","first-page":"270","article-title":"Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs","volume":"25","author":"Okuda","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/jac\/dkq198","article-title":"ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J","volume":"65","author":"Chono","year":"2010","journal-title":"Antimicrob. Chemother."},{"key":"ref_39","first-page":"46","article-title":"New antiviral drugs that target herpesvirus helicase primase enzymes","volume":"10","author":"Kleymann","year":"2003","journal-title":"Herpes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2012.12.006","article-title":"Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus","volume":"97","author":"Chono","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bcp.2012.05.020","article-title":"Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir)","volume":"84","author":"Chono","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/cpt.647","article-title":"Drugs in development for herpes simplex and varicella zoster virus","volume":"102","author":"Birkmann","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/1346-8138.13948","article-title":"Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study","volume":"44","author":"Kawashima","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1386-6532(10)70005-6","article-title":"Management of herpes zoster and post-herpetic neuralgia now and in the future","volume":"48","author":"Whitley","year":"2010","journal-title":"J. Clin. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1086\/378503","article-title":"Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells","volume":"188","author":"Levy","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1086\/522125","article-title":"The safety profile of varicella vaccine: A 10-year review","volume":"197","author":"Galea","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/INF.0b013e318170af75","article-title":"Vaccine-strain varicella zoster virus causing recurrent herpes zoster in an immunocompetent 2-year-old","volume":"27","author":"Ota","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00431-002-0981-1","article-title":"Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child","volume":"161","author":"Uebe","year":"2002","journal-title":"Eur. J. Pediatr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/cid\/ciu058","article-title":"Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine","volume":"58","author":"Tseng","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jcv.2010.04.014","article-title":"VZV meningitis following varicella vaccine","volume":"48","author":"Fusco","year":"2010","journal-title":"J. Clin. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/INF.0b013e3181f63cf9","article-title":"Herpes zoster and meningitis due to reactivation of varicella vaccine virus in an immunocompetent child","volume":"30","author":"Han","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e969","DOI":"10.1542\/peds.2009-2633","article-title":"Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child","volume":"125","author":"Chouliaras","year":"2010","journal-title":"Pediatrics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/imj.14178","article-title":"Vaccine strain varicella zoster virus transmitted within a family from a child with shingles results in varicella meningitis in an immunocompetent adult","volume":"49","author":"Davidson","year":"2019","journal-title":"Intern. Med. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1001\/jama.1988.03410190127035","article-title":"Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS","volume":"260","author":"Pahwa","year":"1988","journal-title":"JAMA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/jmv.1890420404","article-title":"Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient","volume":"42","author":"Snoeck","year":"1994","journal-title":"J. Med. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/infdis\/170.1.68","article-title":"Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS","volume":"170","author":"Boivin","year":"1994","journal-title":"J. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1128\/jvi.67.2.1024-1033.1993","article-title":"Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS","volume":"67","author":"Talarico","year":"1993","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","article-title":"Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: Diagnosis and management","volume":"29","author":"Piret","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_59","first-page":"335","article-title":"Persistence and Antiviral Resistance of Varicella Zoster Virus in Hematological Patients","volume":"56","author":"Vermont","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/cid\/cir079","article-title":"Compartmentalization of acyclovir-resistant varicella zoster virus: Implications for sampling in molecular diagnostics","volume":"52","author":"Brink","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcv.2013.04.024","article-title":"Acyclovir-resistant varicella-zoster virus keratitis in an immunocompetent patient","volume":"58","author":"Gueudry","year":"2013","journal-title":"J. Clin. Virol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1368-7646(02)00021-3","article-title":"Resistance of herpesviruses to antiviral drugs: Clinical impacts and molecular mechanisms","volume":"5","author":"Gilbert","year":"2002","journal-title":"Drug Resist. Updates"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/JVI.06620-11","article-title":"In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs","volume":"86","author":"Andrei","year":"2012","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.01.003","article-title":"Thymidine kinase and protein kinase in drug-resistant herpesviruses: Heads of a Lernaean Hydra","volume":"37","author":"Topalis","year":"2018","journal-title":"Drug Resist. Updates"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1128\/AAC.43.10.2412","article-title":"Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir","volume":"43","author":"Morfin","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/rmv.1787","article-title":"Antiviral drug resistance in herpesviruses other than cytomegalovirus","volume":"24","author":"Piret","year":"2014","journal-title":"Rev. Med. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/INF.0b013e3181598315","article-title":"Foscarnet salvage therapy for acyclovir-resistant varicella zoster: Report of a novel thymidine kinase mutation and review of the literature","volume":"27","author":"Hatchette","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-115-1-19","article-title":"Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection","volume":"115","author":"Safrin","year":"1991","journal-title":"Ann. Intern. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/INF.0b013e318175d85c","article-title":"Acyclovir-resistant chronic verrucous vaccine strain varicella in a patient with neuroblastoma","volume":"27","author":"Bryan","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1086\/514257","article-title":"Single amino acid change in DNA polymerase is associated with foscarnet resistance in a varicella-zoster virus strain recovered from a patient with AIDS","volume":"178","author":"Visse","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/clinids\/21.5.1348","article-title":"Foscarnet-resistant multidermatomal zoster in a patient with AIDS","volume":"21","author":"Fillet","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/(SICI)1096-9071(199909)59:1<84::AID-JMV14>3.0.CO;2-N","article-title":"Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype","volume":"59","author":"Visse","year":"1999","journal-title":"J. Med. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.antiviral.2003.10.003","article-title":"In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): Differences between acyclovir and penciclovir?","volume":"61","author":"Andrei","year":"2004","journal-title":"Antivir. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1128\/AAC.31.8.1238","article-title":"Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob","volume":"31","author":"Boyd","year":"1987","journal-title":"Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0166-3542(97)00054-5","article-title":"Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants","volume":"37","author":"Pelosi","year":"1998","journal-title":"Antivir. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0166-3542(95)00007-9","article-title":"Inhibitory action of acyclovir (ACV) and penciclovir (PCV) on plaque formation and partial cross-resistance of ACV-resistant varicella-zoster virus to PCV","volume":"27","author":"Hasegawa","year":"1995","journal-title":"Antivir. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0166-3542(98)00057-6","article-title":"Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants","volume":"40","author":"Ida","year":"1999","journal-title":"Antivir. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/09273948.2016.1207788","article-title":"Treatment of Refractory Acute Retinal Necrosis with Intravenous Foscarnet or Cidofovir","volume":"26","author":"Stryjewski","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.clinthera.2018.07.006","article-title":"Antiviral Therapies for Herpesviruses: Current Agents and New Directions","volume":"40","author":"Poole","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1086\/378502","article-title":"Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child","volume":"188","author":"Levin","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1021\/jm990346o","article-title":"Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base","volume":"42","author":"McGuigan","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/jm000210m","article-title":"Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain","volume":"43","author":"McGuigan","year":"2000","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1128\/AAC.49.3.1081-1086.2005","article-title":"Susceptibilities of several clinical Varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0925-4439(02)00091-1","article-title":"Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides","volume":"1587","author":"Balzarini","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jac\/dkm376","article-title":"Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus","volume":"60","author":"McGuigan","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1081\/NCN-120022721","article-title":"Metabolic and pharmacological characteristics of the bicyclic nucleoside analogues (BCNAs) as highly selective inhibitors of varicella-zoster virus (VZV)","volume":"22","author":"Sienaert","year":"2003","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1124\/mol.61.5.1140","article-title":"Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase","volume":"61","author":"Balzarini","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1124\/mol.61.2.249","article-title":"Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase","volume":"61","author":"Sienaert","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1128\/AAC.01446-10","article-title":"Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers","volume":"55","author":"Pentikis","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/jmv.24750","article-title":"FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial","volume":"89","author":"Tyring","year":"2017","journal-title":"J. Med. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1128\/AAC.32.8.1137","article-title":"Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine triphosphate","volume":"32","author":"Abele","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1128\/AAC.39.8.1802","article-title":"Mode of action of (R)-9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine against herpesviruses","volume":"39","author":"Lowe","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1128\/AAC.45.6.1629-1636.2001","article-title":"Selection and characterization of varicella-zoster virus variants resistant to (R)-9-(4-hydroxy-2-(hydroxymethy)butyl)guanine","volume":"45","author":"Ng","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1128\/AAC.42.12.3285","article-title":"The antiherpesvirus activity of H2G ((R)-9-(4-hydroxy-2-(hydroxymethyl)butyl)guanine) is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil","volume":"42","author":"Neyts","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0706446","article-title":"Antiviral prodrugs-the development of successful prodrug strategies for antiviral chemotherapy","volume":"147","author":"Field","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/jmv.23329","article-title":"Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: A randomized, double-blind, active-controlled trial","volume":"84","author":"Tyring","year":"2012","journal-title":"J. Med. Virol."},{"key":"ref_97","unstructured":"Balfour, H.H., Vezina, H.E., Hogquist, R.C., Brundage, R.C., Anderson, B.J., and Odumade, O.A. (2009, January 14). Randomized, placebo-controlled, double-blind trial of valomacicovir (VALM) for infectious mononucleosis (IM). Proceedings of the 49th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: Current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antiviral. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob","volume":"46","author":"Beadle","year":"2002","journal-title":"Agents Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1111\/tid.12977","article-title":"Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients","volume":"20","author":"Lee","year":"2018","journal-title":"Transpl. Infect. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/tid.12583","article-title":"Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host","volume":"18","author":"Mullane","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.2174\/0929867323666160510123023","article-title":"Advances of Phenoxazines: Synthesis, Reactivity and Their Medicinal Applications","volume":"23","author":"Katsamakas","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2019.01.010","article-title":"Antiviral activity spectrum of phenoxazine nucleoside derivatives","volume":"163","author":"Kozlovskaya","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1254\/jphs.FP0071679","article-title":"Phenoxazine derivatives inactivate human cytomegalovirus, herpes simplex virus-1, and herpes simplex virus-2 in vitro","volume":"106","author":"Hayashi","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejmech.2017.12.018","article-title":"Emimycin and its nucleoside derivatives: Synthesis and antiviral activity","volume":"144","author":"Plebanek","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejmech.2012.04.001","article-title":"Synthesis and antiviral evaluation of C5-substituted-(1,3-diyne)-2\u2032-deoxyuridines","volume":"53","author":"Sari","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bmc.2012.09.051","article-title":"C-3 halo and 3-methyl substituted 5\u2032-nor-3-deazaaristeromycins: Synthesis and antiviral properties","volume":"21","author":"Liu","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1177\/2040206618813050","article-title":"Xanthine-based acyclic nucleoside phosphonates with potent antiviral activity against varicella-zoster virus and human cytomegalovirus","volume":"26","author":"Baszczynski","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ejmech.2018.03.008","article-title":"Synthesis and antiviral evaluation of cyclopentyl nucleoside phosphonates","volume":"150","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejmech.2018.01.086","article-title":"Highly convergent synthesis and antiviral activity of (E)-but-2-enyl nucleoside phosphonoamidates","volume":"146","author":"Bessieres","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1021\/jm1011462","article-title":"Novel antiviral C5-substituted pyrimidine acyclic nucleoside phosphonates selected as human thymidylate kinase substrates","volume":"54","author":"Topalis","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.antiviral.2017.04.013","article-title":"Phosphonoamidate prodrugs of C5-substituted pyrimidine acyclic nucleosides for antiviral therapy","volume":"143","author":"Pertusati","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1016\/j.bmc.2017.06.046","article-title":"New prodrugs of two pyrimidine acyclic nucleoside phosphonates: Synthesis and antiviral activity","volume":"25","author":"Krecmerova","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"6220","DOI":"10.1021\/acs.jmedchem.7b00416","article-title":"Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs","volume":"60","author":"Luo","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/acsmedchemlett.8b00079","article-title":"Amidate Prodrugs of Cyclic 9-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]adenine with Potent Anti-Herpesvirus Activity","volume":"9","author":"Luo","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"12198","DOI":"10.1128\/JVI.01280-12","article-title":"Identification of a varicella-zoster virus replication inhibitor that blocks capsid assembly by interacting with the floor domain of the major capsid protein","volume":"86","author":"Inoue","year":"2012","journal-title":"J. Virol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/1348-0421.12507","article-title":"Characterization of an anti-varicella-zoster virus compound that targets the portal protein encoded by ORF54","volume":"61","author":"Yasui","year":"2017","journal-title":"Microbiol. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.antiviral.2017.01.024","article-title":"Characterization of a thienylcarboxamide derivative that inhibits the transactivation functions of cytomegalovirus IE2 and varicella zoster virus IE62","volume":"140","author":"Majima","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ejmech.2016.09.014","article-title":"Identification of an indol-based derivative as potent and selective varicella zoster virus (VZV) inhibitor","volume":"124","author":"Musella","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12275-019-8514-z","article-title":"Anti-varicella-zoster virus activity of cephalotaxine esters in vitro","volume":"57","author":"Kim","year":"2019","journal-title":"J. Microbiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ejmech.2018.06.028","article-title":"Dihydropyrimidinone\/1,2,3-triazole hybrid molecules: Synthesis and anti-varicella-zoster virus (VZV) evaluation","volume":"155","author":"Kaoukabi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Gupta, A., Dixit, B., Stamoulas, K., and Akshikar, R. (2020). Atypical bilateral acute retinal necrosis in a coronavirus disease 2019 positive immunosuppressed patient. Eur. J. Ophthalmol., 4941.","DOI":"10.1177\/1120672120974941"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/ijd.15001","article-title":"Herpes zoster in COVID-19-positive patients","volume":"59","author":"Tartari","year":"2020","journal-title":"Int. J. Dermatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jdcr.2020.05.012","article-title":"Herpes zoster and severe acute herpetic neuralgia as a complication of COVID-19 infection","volume":"6","author":"Shors","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1111\/dth.13666","article-title":"Herpes zoster might be an indicator for latent COVID 19 infection","volume":"33","author":"Elsaie","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/ene.14361","article-title":"COVID-19 and herpes zoster co-infection presenting with trigeminal neuropathy","volume":"27","author":"Ferreira","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"ref_128","first-page":"8998","article-title":"Herpes Zoster Co-Infection in an Immunocompetent Patient with COVID-19","volume":"12","author":"Saati","year":"2020","journal-title":"Cureus"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/4\/1132\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:27:07Z","timestamp":1760160427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/4\/1132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,20]]},"references-count":128,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["molecules26041132"],"URL":"https:\/\/doi.org\/10.3390\/molecules26041132","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,20]]}}}